Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222443 · ClinicalTrials.gov registry record · Phase 1
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
A Phase 1 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00222443 is a Phase 1 study that has completed, run by University of Oklahoma. The registered enrollment target is 40 participants.
The verdict
NCT00222443, a Phase 1 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the response rate to this combination in children and adolescents with recurrent solid tumors and lymphomas.
Interventions
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222443
The ClinicalTrials.gov registry entry for NCT00222443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan is the first listed.
NCT00222443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222443 about?
NCT00222443 is a clinical study titled "Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy". Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the response rate to this combination in children and adolescents with recu...
What is the current status of trial NCT00222443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00222443?
The interventions under investigation include: Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00222443?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.